<DOC>
	<DOCNO>NCT00762632</DOCNO>
	<brief_summary>This nonrandomized , open-label study evaluate efficacy safety combination treatment Nilotinib RAD001 treatment c-kit + AML . Patients refractory standard chemotherapy eligible standard chemotherapy include . Patients treat 400 mg Nilotinib bid ( total daily dose 800 mg ) . RAD001 add treatment duration 1 week dosage 2,5 mg/day . Treatment duration 25 week .</brief_summary>
	<brief_title>Combination Nilotinib ( AMN107 ) RAD001 Patients With Acute Myeloid Leukemia</brief_title>
	<detailed_description />
	<mesh_term>Leukemia</mesh_term>
	<mesh_term>Leukemia , Myeloid</mesh_term>
	<mesh_term>Leukemia , Myeloid , Acute</mesh_term>
	<mesh_term>Everolimus</mesh_term>
	<mesh_term>Sirolimus</mesh_term>
	<criteria>Inclusion criterion : 1 . Patients : De novo AML secondary AML MDS candidate myelosuppressive chemotherapy , De novo AML secondary AML MDS relapse disease refractory standard therapy 2 . Patients least 18 year old 3 . Patients WHO performance status 0 2 life expectancy treatment least 3 month 4 . Patients must recover prior cytotoxic chemotherapy ; treatment Hydroxyurea AraC allow 24 hour first administration study drug . 5 . Patients must serum creatinine &lt; = 1.5 x ULN , SGOT/SGPT &lt; = 3 x ULN total bilirubin &lt; = 2.0 x ULN 6 . Female patient childbearing potential must negative pregnancy test within 7 day initiation study drug dosing . Postmenopausal woman must amenorrheic least 12 month consider nonchildbearing potential . 7 . Written inform consent obtain accord local guideline Exclusion criterion : 1 . Patients AML FAB M3 . 2 . Patients expect double peripheral blast within one week . 3 . Patients prior allogeneic , syngeneic , autologous bone marrow transplant stem cell transplant le 2 month previously . 4 . Impaired cardiac function , include one following : LVEF &lt; 45 % institutional low limit normal range ( whichever high ) determine MUGA scan echocardiogram Complete leave bundle branch block Use cardiac pacemaker ST depression &gt; 1mm 2 lead and/or T wave inversion 2 contiguous lead Congenital long QT syndrome dose level 400 1200 mg QD . Many common adverse event report imatinib Phase II leukemia ( STI0106 , STI0110 ) study also report nilotinib Phase I study , although notably low frequency peripheral edema identify nilotinib study . History presence significant ventricular atrial tachyarrhythmias Clinically significant rest bradycardia ( &lt; 50 beat per minute ) QTc &gt; 450 msec screen ECG ( use QTcF formula ) QT prolong concomitant medication Right bundle branch block plus leave anterior hemiblock , bifascicular block Myocardial infarction within 12 month prior start Nilotinib Unstable angina diagnose treat past 12 month Other clinically significant heart disease ( e.g. , congestive heart failure , uncontrolled hypertension , history labile hypertension , history poor compliance antihypertensive regimen ) 5 . Female patient pregnant breast feeding , adult childbearing age employ effective method birth control . 6 . Concurrent severe and/or uncontrolled medical psychiatric condition may interfere completion study . 7 . Patients 2 prior regimen current relapse current primary refractory disease 8 . Patients uncontrolled active infection . 9 . Patient pulmonary infiltrate baseline chest Xray know new previous 4 week . Prior treatment investigational drug within precede 4 week 10 . Chronic treatment systemic steroid another immunosuppressive agent 11 . Uncontrolled brain leptomeningeal metastasis , include patient continue require glucocorticoid brain leptomeningeal metastases 12 . Other malignancy within past 3 year except adequately treat carcinoma cervix basal squamous cell carcinoma skin . 13 . Other concurrent severe and/or uncontrolled medical disease could compromise participation study ( i.e. , uncontrolled diabetes , uncontrolled hypertension , severe infection , severe malnutrition , unstable angina , congestive heart failure New York Heart Association Class III IV , ventricular arrhythmia active ischemic heart disease , myocardial infarction within six month , chronic liver renal disease , active upper GI tract ulceration ) 14 . A known history HIV seropositivity 15 . Impairment gastrointestinal function gastrointestinal disease may significantly alter absorption RAD001 ( e.g. , ulcerative disease , uncontrolled nausea , vomit , diarrhea , malabsorption syndrome small bowel resection ) 16 . Patients active , bleed diathesis oral antivitamin K medication ( except low dose coumarin ) 17 . Hypokalemia 18 . Women pregnant breast feeding , woman able conceive unwilling practice highly effective method birth control . 19 . Patients receive prior treatment mTor inhibitor . 20 . History noncompliance medical regimen 21 . Patients unwilling unable comply protocol</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>August 2012</verification_date>
	<keyword>patient c-kit+ AML</keyword>
</DOC>